Literature DB >> 27649371

An homozygous mutation in KCNK3 is associated with an aggressive form of hereditary pulmonary arterial hypertension.

P Navas Tejedor1,2, J Tenorio Castaño3,4,5, J Palomino Doza6, P Arias Lajara3,4,5, G Gordo Trujillo3,4,5, M López Meseguer7, A Román Broto7, P Lapunzina Abadía3,4,5, P Escribano Subía2,8.   

Abstract

Pulmonary arterial hypertension (PAH) is a rare devastating disease characterized by a high genetic heterogeneity with several related genes recently described, including BMPR2,TBX4 and KCNK3. The association between KCNK3 and PAH has been recently identified, but the prognosis and phenotype associated with these mutations have been poorly described. We studied a series of 136 idiopathic and hereditary PAH Spanish patients for BMPR2, TBX4 and KCNK3 mutations. We report the results of KCNK3 in which we were able to describe two new mutations (p.Gly106Arg and p.Leu214Arg) in three patients. The first one was found in a patient belonging to a consanguineous Romani family, who carried a homozygous mutation in KCNK3 and developed a severe and early form of the disease. To the best of our knowledge, this is the first time that a homozygous mutation in KCNK3 is reported in a PAH patient. The second one was found in a patient who presented at the young adult age a severe form of the disease. The present report supports the contribution of KCNK3 mutations to the genetic etiology of PAH and strongly suggests that mutations in KCNK3 follow incomplete dominance with worsening of the clinical features in homozygous patients.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  KCNK3; hereditary pulmonary arterial hypertension; idiopathic pulmonary arterial hypertension; incomplete dominance; screening

Mesh:

Substances:

Year:  2016        PMID: 27649371     DOI: 10.1111/cge.12869

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  19 in total

Review 1.  Pulmonary Hypertension and ATP-Sensitive Potassium Channels.

Authors:  Conor McClenaghan; Kel Vin Woo; Colin G Nichols
Journal:  Hypertension       Date:  2019-05-28       Impact factor: 10.190

Review 2.  'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension.

Authors:  Emilia M Swietlik; Matina Prapa; Jennifer M Martin; Divya Pandya; Kathryn Auckland; Nicholas W Morrell; Stefan Gräf
Journal:  Genes (Basel)       Date:  2020-11-26       Impact factor: 4.096

Review 3.  Molecular basis of the association between transcription regulators nuclear respiratory factor 1 and inhibitor of DNA binding protein 3 and the development of microvascular lesions.

Authors:  Christian Michael Perez; Quentin Felty
Journal:  Microvasc Res       Date:  2022-02-07       Impact factor: 3.514

4.  Exome Sequencing in Children With Pulmonary Arterial Hypertension Demonstrates Differences Compared With Adults.

Authors:  Na Zhu; Claudia Gonzaga-Jauregui; Carrie L Welch; Lijiang Ma; Hongjian Qi; Alejandra K King; Usha Krishnan; Erika B Rosenzweig; D Dunbar Ivy; Eric D Austin; Rizwan Hamid; William C Nichols; Michael W Pauciulo; Katie A Lutz; Ashley Sawle; Jeffrey G Reid; John D Overton; Aris Baras; Frederick Dewey; Yufeng Shen; Wendy K Chung
Journal:  Circ Genom Precis Med       Date:  2018-04

Review 5.  Molecular genetic framework underlying pulmonary arterial hypertension.

Authors:  Laura Southgate; Rajiv D Machado; Stefan Gräf; Nicholas W Morrell
Journal:  Nat Rev Cardiol       Date:  2019-08-12       Impact factor: 32.419

6.  TASK-1 potassium channel is not critically involved in mediating hypoxic pulmonary vasoconstriction of murine intra-pulmonary arteries.

Authors:  Ghulam Murtaza; Petra Mermer; Anna Goldenberg; Uwe Pfeil; Renate Paddenberg; Nobert Weissmann; Guenter Lochnit; Wolfgang Kummer
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

7.  KCNK3 Mutation Causes Altered Immune Function in Pulmonary Arterial Hypertension Patients and Mouse Models.

Authors:  James D West; Eric D Austin; Elise M Rizzi; Ling Yan; Harikrishna Tanjore; Amber L Crabtree; Christy S Moore; Gladson Muthian; Erica J Carrier; David A Jacobson; Rizwan Hamid; Peggy L Kendall; Susan Majka; Anandharajan Rathinasabapathy
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

8.  The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels.

Authors:  Kevin P Cunningham; Lucie H Clapp; Alistair Mathie; Emma L Veale
Journal:  Front Pharmacol       Date:  2021-06-29       Impact factor: 5.810

9.  In vivo miR-138-5p inhibition alleviates monocrotaline-induced pulmonary hypertension and normalizes pulmonary KCNK3 and SLC45A3 expression.

Authors:  Hélène Le Ribeuz; Audrey Courboulin; Maria-Rosa Ghigna; Mélanie Lambert; Aurélie Hautefort; Marc Humbert; David Montani; Sylvia Cohen-Kaminsky; Frédéric Perros; Fabrice Antigny
Journal:  Respir Res       Date:  2020-07-16

10.  Characterization of rare ABCC8 variants identified in Spanish pulmonary arterial hypertension patients.

Authors:  Mauro Lago-Docampo; Jair Tenorio; Ignacio Hernández-González; Carmen Pérez-Olivares; Pilar Escribano-Subías; Guillermo Pousada; Adolfo Baloira; Miguel Arenas; Pablo Lapunzina; Diana Valverde
Journal:  Sci Rep       Date:  2020-09-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.